Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation & Amortization: 2020-2023

Historic Accumulated Depreciation & Amortization for Candel Therapeutics (CADL) over the last 4 years, with Sep 2023 value amounting to $1.8 million.

  • Candel Therapeutics' Accumulated Depreciation & Amortization rose 820.00% to $1.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.4 million, marking a year-over-year increase of 227.08%. This contributed to the annual value of $800,000 for FY2022, which is 300.00% up from last year.
  • Candel Therapeutics' Accumulated Depreciation & Amortization amounted to $1.8 million in Q3 2023, which was up 820.00% from $200,000 recorded in Q2 2023.
  • Candel Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $1.8 million during Q3 2023, with a 5-year trough of $6,000 in Q4 2020.
  • In the last 3 years, Candel Therapeutics' Accumulated Depreciation & Amortization had a median value of $200,000 in 2023 and averaged $294,636.
  • Per our database at Business Quant, Candel Therapeutics' Accumulated Depreciation & Amortization tumbled by 61.11% in 2021 and then spiked by 2,757.14% in 2022.
  • Quarterly analysis of 4 years shows Candel Therapeutics' Accumulated Depreciation & Amortization stood at $6,000 in 2020, then spiked by 2,333.33% to $146,000 in 2021, then soared by 36.99% to $200,000 in 2022, then skyrocketed by 820.00% to $1.8 million in 2023.
  • Its Accumulated Depreciation & Amortization stands at $1.8 million for Q3 2023, versus $200,000 for Q2 2023 and $200,000 for Q1 2023.